LAP (mut) IL-2 T peptide - Stealthyx Therapeutics

Alternative Names: LAP (mut) IL-2 T; LAP-(mut)IL-2T peptide; Latency Associated Peptide

Latest Information Update: 17 Jun 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stealthyx
Developer Queen Mary University of London; Stealthyx
Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Apr 2021 Preclinical trials in Malignant melanoma in United Kingdom (Intraperitoneal) prior to April 2021
10 Apr 2021 Preclinical trials in Renal cancer in United Kingdom (Intraperitoneal) prior to April 2021
10 Apr 2021 Pharmacodynamic and safety data from a preclinical trial in Renal cancer and Malignant melanoma presented at 112th Annual Meeting of the American Association for Cancer Research(AACR-2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com